INIT: Q1 2025 saw reduced losses and clinical progress in ED, FSD, and pain programs

About this update from Initiator Pharma A/s

Initiator Pharma reported a reduced Q1 2025 net loss and advanced its clinical pipeline, with strong progress in sexual health and pain programs and expanded leadership. The company remains focused on new clinical phases, partnerships, and securing future financing.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Initiator Pharma A/s